Literature DB >> 3485528

Quantitative and qualitative differences in HLA-DR molecules correlated with antigen-presentation capacity.

R Bontrop, T Ottenhoff, R Van Miltenburg, D Elferink, R De Vries, M Giphart.   

Abstract

The monoclonal antibodies 7.3.19.1 (anti-DRw52-like) and B8.11.2 (anti-DR framework) were used for the isolation and characterization of HLA class II molecules expressed by HLA-DR3 and DR5 homozygous B cell lines. Sequential immunoprecipitation studies demonstrated that from these cells class II molecules can be isolated which are characterized by the presence or absence of DR framework (DR) and DRw52-like (DRw62) determinants: (DR+, DRw52+), (DR+, DRw52-) and (DR-, DRw52+). The DR3 donor cells appeared to express only the (DR+, DRw52+) and (DR-, DRw52+) class II molecules whereas DR5-positive cells express only the (DR+, DRw52+) and (DR+, DRw52-) class II molecules. Besides qualitative differences some of the above-mentioned molecules appeared to differ in their levels of expression. To investigate whether this might have functional implications, cells with the HLA-DR3 and -5 haplotypes were used to present antigen purified protein derivative of tuberculin (PPD) to PPD-specific T cell lines and the blocking capacity of the two monoclonal antibodies 7.3.19.1 and B8.11.2 was determined. A remarkable correlation was observed between the type of class II molecule blocked by these monoclonal antibodies and its quantitative expression. However, (DR-, DRw52+) molecules, clearly expressed by DR3 cells, were not involved in the presentation of PPD. This indicates that not only quantitative but also qualitative aspects may play a role in the selection of the type of class II molecule that will be involved in antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485528     DOI: 10.1002/eji.1830160205

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Polymorphisms within the HLA-DR3 haplotypes. I. HLA-DR polymorphisms detected at the protein and DNA levels are reflected by T-cell recognition.

Authors:  R Bontrop; M Tilanus; M Mikulski; M van Eggermond; A Termijtelen; M Giphart
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Polymorphism and complexity of HLA-DR: evidence for intra-HLA-DR region crossing-over events.

Authors:  R E Bontrop; M G Tilanus; M M Mikulski; D G Elferink; A Termijtelen; R R de Vries; J J van Rood; M J Giphart
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

3.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

Review 4.  Regulation of major histocompatibility complex class II gene expression, genetic variation and disease.

Authors:  L Handunnetthi; S V Ramagopalan; G C Ebers; J C Knight
Journal:  Genes Immun       Date:  2009-11-05       Impact factor: 2.676

5.  Polymorphism in both X and Y box motifs controls level of expression of HLA-DRB1 genes.

Authors:  D P Singal; X Qiu
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

6.  Major histocompatibility complex class II-restricted antigen presentation across a species barrier: conservation of restriction determinants in evolution.

Authors:  R E Bontrop; D G Elferink; N Otting; M Jonker; R R de Vries
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

7.  Functional polymorphism of each of the two HLA-DR beta chain loci demonstrated with antigen-specific DR3- and DRw52-restricted T cell clones.

Authors:  C Irlé; D Jaques; J M Tiercy; S V Fuggle; J Gorski; A Termijtelen; M Jeannet; B Mach
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

8.  Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer. Definition of DR2 beta gene products and antigen presentation to T cell clones from leprosy patients.

Authors:  D Wilkinson; R R de Vries; J A Madrigal; C B Lock; J P Morgenstern; J Trowsdale; D M Altmann
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

9.  Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires.

Authors:  Erika Margaret Scholz; Miguel Marcilla; Xavier Daura; David Arribas-Layton; Eddie A James; Iñaki Alvarez
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

10.  Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft.

Authors:  Arieke S B Kampstra; Jurgen van Heemst; George M Janssen; Arnoud H de Ru; Menno van Lummel; Peter A van Veelen; René E M Toes
Journal:  Immunogenetics       Date:  2019-09-13       Impact factor: 2.846

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.